Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
Conditions
Interventions
Palopegteriparatide Experimental Arm
Palopegteriparatide Control Arm
Locations
1
United States
Ascendis Pharma Investigational Site
Reno, Nevada, United States
Start Date
April 16, 2026
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2028
Last Updated
April 22, 2026
NCT07345494
NCT06961071
NCT05793853
NCT07197450
NCT06069583
NCT06765941
Lead Sponsor
Ascendis Pharma Bone Diseases A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions